|
|
|
|
| LEADER |
04429cam a22010097a 4500 |
| 001 |
BIBLO-46433 |
| 003 |
AR-BaUEN |
| 005 |
20240827175405.0 |
| 008 |
130314s2010 xxua|||f |||| 00| 0|eng|d |
| 040 |
|
|
|a AR-BaUEN
|b spa
|c AR-BaUEN
|
| 020 |
|
|
|a 9780323053747
|
| 044 |
|
|
|a xxu
|
| 080 |
|
|
|a 615
|
| 100 |
1 |
|
|a Wecker, Lynn
|
| 245 |
1 |
0 |
|a Brody´s Human pharmacology molecular to clinical
|
| 250 |
|
|
|a 5th. ed.
|
| 260 |
|
|
|a Philadelphia :
|b Mosby Elsevier,
|c 2010
|
| 300 |
|
|
|a xviii, 688 p. + gráf. :
|b il.
|
| 490 |
0 |
|
|a Student CONSULT
|
| 500 |
|
|
|a Incluye: "estudiante CONSULTAR" acceso en linea a disponible (código: en el dorso portada) / Stephanie Watts, ISBN 0323053742
|
| 505 |
0 |
0 |
|g 1
|t Pharmacodynamics: Receptors and Concentrations-Response Relationships
|
| 505 |
0 |
0 |
|g 2
|t Pharmacokinetics: Absorption, Distribution, Metabolism, and Elimination
|
| 505 |
0 |
0 |
|g 3
|t Clinical Pharmacokinetics and Issues in Therapeutics
|
| 505 |
0 |
0 |
|g 4
|t Drug Development, Regulation, and Prescription Writing
|
| 505 |
0 |
0 |
|g 5
|t Gene Therapy and Emerging Molecular Therapies
|
| 505 |
0 |
0 |
|g 6
|t Antibodies and Biological Products
|
| 505 |
0 |
0 |
|g 7
|t HerbalS and Natural Products
|
| 505 |
0 |
0 |
|g 8
|t Principles of Toxicology
|
| 505 |
0 |
0 |
|g 9
|t Introiduction to the Autonomic Nervous System
|
| 505 |
0 |
0 |
|g 10
|t Drugs Affecting the Parasympathetic Nervous System and Autonomic Ganglia
|
| 505 |
0 |
0 |
|g 11
|t Drugs Affecting the Sympathetic Nervous System
|
| 505 |
0 |
0 |
|g 12
|t Skeletal Muscle Relaxants
|
| 505 |
0 |
0 |
|g 13
|t Local Anesthetics
|
| 505 |
0 |
0 |
|g 14
|t Histamine and Antihistamines
|
| 505 |
0 |
0 |
|g 15
|t Prostaglandins and Other Eicosanoids
|
| 505 |
0 |
0 |
|g 16
|t Drugs to Treat Asthma and Chronic Obstructive Pulmonary Disease
|
| 505 |
0 |
0 |
|g 17
|t Drugs Affecting Uterine Motility
|
| 505 |
0 |
0 |
|g 18
|t Drugs Affecting the Gastrointestinal System
|
| 505 |
0 |
0 |
|g 19
|t Introduction to the Regulation of Cardiovascular Function
|
| 505 |
0 |
0 |
|g 20
|t Antihypertensive Drugs
|
| 505 |
0 |
0 |
|g 21
|t Diurethic Drugs
|
| 505 |
0 |
0 |
|g 22
|t Antiarrhythmic Drugs
|
| 505 |
0 |
0 |
|g 23
|t Drugs to Treat Heart Failure
|
| 505 |
0 |
0 |
|g 24
|t Vasodilators and Nitric Oxide Synthase
|
| 505 |
0 |
0 |
|g 25
|t Lipid-Lowering Drugs and Atherosclerosis
|
| 505 |
0 |
0 |
|g 26
|t Antithrombotic Drugs
|
| 505 |
0 |
0 |
|g 27
|t Introduction to the Central Nervous System
|
| 505 |
0 |
0 |
|g 28
|t Treatment of Parkinson's and Alzheimer's Diseases
|
| 505 |
0 |
0 |
|g 29
|t Treatment of Psychotic Disorders
|
| 505 |
0 |
0 |
|g 30
|t Treatment of Affective Disorders
|
| 505 |
0 |
0 |
|g 31
|t Treatment of Anxiety and Insomnia
|
| 505 |
0 |
0 |
|g 32
|t Ethanol, Other Alcohols, and Drugs for Alcohol Dependence
|
| 505 |
0 |
0 |
|g 33
|t Treatment of Obesity and Eating Disorders
|
| 505 |
0 |
0 |
|g 34
|t Treatment of Seizure Disorders
|
| 505 |
0 |
0 |
|g 35
|t General Anesthetics
|
| 505 |
0 |
0 |
|g 36
|t Drugs to Control Pain
|
| 505 |
0 |
0 |
|g 37
|t Drugs and Substance Abuse, Addiction, and Treatment
|
| 505 |
0 |
0 |
|g 38
|t Introduction to Endocrine Pharmacology and Hormones of the Hypothalamus and Pituitary Gland
|
| 505 |
0 |
0 |
|g 39
|t Adrenocorticosteroids
|
| 505 |
0 |
0 |
|g 40
|t Estrogens and Progestins
|
| 505 |
0 |
0 |
|g 41
|t Androgens and Antiandrogens
|
| 505 |
0 |
0 |
|g 42
|t Thyroid and Antithyroid Drugs
|
| 505 |
0 |
0 |
|g 43
|t Insulin and Drugs Used in the Therapy of Diabetes Mellitus
|
| 505 |
0 |
0 |
|g 44
|t Calcium-Regulating Hormones and Other Agents Affecting Bone
|
| 505 |
0 |
0 |
|g 45
|t Principles of Antimicrobial Use
|
| 505 |
0 |
0 |
|g 46
|t Bacterial Cell Wall Synthesis Inhibitors
|
| 505 |
0 |
0 |
|g 47
|t Inhibitors of Bacterial Ribosomal Actions
|
| 505 |
0 |
0 |
|g 48
|t Bacterial Folate Antagonists, Fluoroquinolones, and Other Antibacterial Agents
|
| 505 |
0 |
0 |
|g 49
|t Antimycobacterial Agents
|
| 505 |
0 |
0 |
|g 50
|t Antifungal Agents
|
| 505 |
0 |
0 |
|g 51
|t Antiviral Agents
|
| 505 |
0 |
0 |
|g 52
|t Drugs to Treat Parasitic Infections
|
| 505 |
0 |
0 |
|g 53
|t Principles of Antineoplastic Drug Use
|
| 505 |
0 |
0 |
|g 54
|t Mechanisms of Action of Antineoplastic Drugs
|
| 505 |
0 |
0 |
|g 55
|t Adjuvant Antineoplastic Drugs
|
| 505 |
0 |
0 |
|t Appendix: Answers to Self-Assessment Questions
|
| 505 |
0 |
0 |
|t Index
|
| 653 |
1 |
0 |
|a QUIMIOTERAPIA
|
| 650 |
1 |
7 |
|2 spines
|a FARMACOLOGIA
|
| 650 |
1 |
7 |
|2 spines
|a SISTEMA NERVIOSO
|
| 650 |
1 |
4 |
|a SISTEMA CIRCULATORIO
|
| 700 |
1 |
|
|a Crespo, Lynn M.
|
| 700 |
1 |
|
|a Dunaway, George
|
| 700 |
1 |
|
|a Faingold, Carl
|
| 700 |
1 |
|
|a Watts, Atephanie
|
| 931 |
|
|
|a DQB
|
| 962 |
|
|
|a info:eu-repo/semantics/book
|a info:ar-repo/semantics/libro
|b info:eu-repo/semantics/publishedVersion
|